Nanobiotix announces the selection of its second NanoXray product, NBTX-IV and a collaboration with the National Cancer Institute for development
(Thomson Reuters ONE) -
Characterization studies to be undertaken by the US National Cancer Institute's
Nanotechnology Characterization Laboratory
Paris, France, 26 June, 2013 - NANOBIOTIX (Euronext: NANO), a clinical-stage
nanomedicine company pioneering novel approaches for the local treatment of
cancer, announces the selection of a new product for development, NBTX-IV. It is
the second product of the NanoXray pipeline which is designed for systemic
administration (intravenous injection). This product has been selected by the
National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory
(NCL) for characterization on the basis of its potential to impact cancer
treatment.
NBTX-IV is based on Nanobiotix's proprietary NanoXray platform. It is designed
to be administered intravenously to target deep-seated tumors and lymph nodes
which may have been invaded locally by cancer cells. The product aims to enhance
radiotherapy energy to destroy cancer cells and reduce the subsequent escape of
malignant cells localized in neighboring tissues cells or lymph nodes. Target
indications include lung carcinoma, pancreatic cancer or brain metastases.
As part of the collaboration with NCI, the NCL will perform pre-clinical
characterization of NBTX-IV that will support Nanobiotix's filing of an
Investigational New Drug (IND) with the FDA. In parallel, Nanobiotix will
conduct additional preclinical testing to provide a complete dossier for
submission.
The NCL was established to investigate the use of nanoparticulate material for
the advancement of cancer research and to accelerate the development of
promising and safe nanotechnology-derived cancer therapeutics. It provides
preclinical testing and consultation services on a competitive basis to
developers, like Nanobiotix, and is working in concert with other US agencies
such as the U.S. Food and Drug Administration (FDA) to accelerate the transition
of basic nanomedicine research into clinical applications.
"The selection of a second NanoXray product for development coupled with the
characterization being undertaken by the NCL is an important strategic step for
Nanobiotix," said Laurent Levy, CEO of Nanobiotix. "This collaboration with the
NCL will hopefully accelerate the pre-clinical development of NBTX-IV, opening
the pathway for new clinical indications in addition to the one covered by our
first product. The results of the characterization are not only important for
our future IND submission, but also raise our profile in the US market."
-ENDS-
About NANOBIOTIX
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage
nanomedicine company pioneering novel approaches for the local treatment of
cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances
radiotherapy energy to provide a new, more efficient treatment for cancer
patients. NanoXray products are compatible with current radiotherapy treatments
and are meant to treat a wide variety of cancers via multiple routes of
administration. Nanobiotix's lead product NBTXR3, based on NanoXray, is
currently under clinical development for soft tissue sarcoma. The Company has
partnered with PharmaEngine for clinical development and commercialization of
NBTXR3 in Asia. The Company is based in Paris, France.
For more information, please visit www.nanobiotix.com
About NANOXRAY
Nanobiotix's first-in-class, proprietary technology called NanoXray is at the
forefront of a new era of nanomedicine, where nanoparticles are not just a
vehicle for targeted drug delivery, but have become the principal active
element. The NanoXray technology is based on the physical properties of hafnium-
oxide nanoparticles and is used to enhance the efficacy of radiotherapy
treatment for a variety of cancer indications.
Nanoparticles are designed to enter tumor cells and, upon activation by a
standard dose of radiation, they emit large amounts of electrons resulting in
the generation of free radicals that destroy cancer cells (the same mode of
action than radiotherapy but largely amplified). Nanoparticle-enhanced
radiotherapy therefore amplifies the lethal dose of energy locally within the
tumor without changing the effect of the dose passing through surrounding
healthy tissues.
By changing the coating of the nanoparticles, Nanobiotix is developing three
different products that can be administered either by direct injection into the
tumor (NBTXR3), intravenous injection (NBTX-IV) or topical application to fill
tumor cavities after surgery (NBTX-TOPO). The product applied will depend on
type of tumor and the patient's specific clinical needs. NanoXray products are
classified as a medical device in Europe and as a drug in the US. They are
compatible with current radiotherapy methods with respect to equipment and
protocols, as well as with older radiotherapy equipment or any radiation-based
therapy.
For more information, please contact:
Nanobiotix Yucatan
Laurent Levy Media relations (France)
CEO Annie-Florence Loyer/
+33 (0)1 40 26 07 55 Nadège Le Lezec
laurent.levy(at)nanobiotix.com +33 (0)1 53 63 27 27 / +33 (0)6 88 20 35 59
afloyer(at)yucatan.fr
NewCap. College Hill
Financial communication Media relations (Outside France)
and investors relations Melanie Toyne Sewell / Donia Al Saffar
Louis-Victor Delouvrier / +44 (0) 207 457 2020
Emmanuel Huynh nanobiotix(at)collegehill.com
+33 (0)1 44 71 98 53
lvdelouvrier(at)newcap.fr
Disclaimer
This press release contains certain forward-looking statements concerning
Nanobiotix and its business. Such forward-looking statements are based on
assumptions that Nanobiotix considers to be reasonable. However, there can be no
assurance that the estimates contained in such forward-looking statements will
be verified, which estimates are subject to numerous risks including the risks
set forth in the 2012 financial annual report of Nanobiotix (a copy of which is
available on www.nanobiotix.com) and to the development of economic conditions,
financial markets and the markets in which Nanobiotix operates. The forward-
looking statements contained in this press release are also subject to risks not
yet known to Nanobiotix or not currently considered material by Nanobiotix. The
occurrence of all or part of such risks could cause actual results, financial
conditions, performance or achievements of Nanobiotix to be materially different
from such forward-looking statements.
This press release and the information that it contains do not constitute an
offer to sell or subscribe for, or a solicitation of an offer to purchase or
subscribe for, Nanobiotix shares in any country.
Press Release (PDF):
http://hugin.info/157012/R/1711959/568046.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: NANOBIOTIX via Thomson Reuters ONE
[HUG#1711959]
Datum: 26.06.2013 - 08:00 Uhr
Sprache: Deutsch
News-ID 273293
Anzahl Zeichen: 8529
contact information:
Town:
Paris
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 119 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nanobiotix announces the selection of its second NanoXray product, NBTX-IV and a collaboration with the National Cancer Institute for development"
steht unter der journalistisch-redaktionellen Verantwortung von
NANOBIOTIX (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
